Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 1;2(2):e22764.
doi: 10.4161/onci.22764.

Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy

Alexander M Lesokhin  1 , Taha Merghoub, Jedd D Wolchok
Affiliations

Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy

Alexander M Lesokhin et al. Oncoimmunology. .

Abstract

Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer.

Keywords: CCR2; GM-CSF; adoptive T-cell transfer; immunotherapy; myeloid derived suppressor cells.

PubMed Disclaimer

Figures

None
Figure 1. Targeting MDSCs to improve the therapeutic outcome of anticancer immunotherapy. (A) The accumulation of myeloid derived suppressor cells (MDSCs) at the tumor site leads to the formation of peroxynitrite via the concerted action of inducible nitric oxide synthetase (iNOS) and arginase. The nitrosylation of substrates such as CCL2 constitutes one mechanism limiting the intratumoral accumulation of CD8+ T cells. (B) The ablation of MDSCs limits CCL2 nitrosylation, enhances antigen specific CD8+ T-cell activation, and allows for the intratumoral accumulation of T cells, leading to tumor shrinkage.
See this image and copyright information in PMC

References

    1. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935–45. doi: 10.1172/JCI27745. - DOI - PMC - PubMed
    1. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi: 10.1038/nrc3245. - DOI - PubMed
    1. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012;72:876–86. doi: 10.1158/0008-5472.CAN-11-1792. - DOI - PMC - PubMed
    1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74. doi: 10.1038/nri2506. - DOI - PMC - PubMed
    1. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162:5728–37. - PMC - PubMed

LinkOut - more resources